Session1: Assessing the immunogenicity risk of Peptide-related impurities

- Product-Related Impurities: Truncations, duplications, oxidations, glycosylation, etc.





Session1: Assessing the immunogenicity risk of Peptide-related impurities

- Product-Related Impurities: truncations, duplications, oxidations, glycosylation, etc.



- **Narasimha Rao SP, MSc:** ***Adaptive Immunogenicity Risk Mitigation of Generic Peptide Drug Products – A Perspective from a Company***
- **Anne (Annie) De Groot, MD:** ***Considering Tolerance When Evaluating Immunogenicity Risk: In Silico and In Vitro***
- **Robert (Rob) Siegel, PhD:** ***Tiered, Data-driven Approach for Assessing the Safety of Peptide-Related Impurities in Support of Commercial Control Strategy Development***
- **Sophie Tourdot, PhD:** ***In Vitro Assays to Screen T-Cell Responses***
- **Mohanraj Manangeeswaran, PhD:** ***Review, Challenges, Suitability Standards***

➢ Please hold your questions for the panel discussion at the end